SEPTInvestingStart Free

BDRX 424B3: Secondary offering

Biodexa Pharmaceuticals

Filed with the SEC on · accession 0001214659-26-012602

BDRX filed a 424B3 (prospectus (offering)) with the SEC on Oct 6, 2026. Biodexa Pharmaceuticals filed a 424B3 prospectus for the resale of up to 220,421,800 ordinary shares represented by 4,408,436 American Depositary Shares issuable upon exercise of Series P warrants from a September 2026 private placement. The stock moved -3.1% by the first close after the filing.

Summary of the filing

Biodexa Pharmaceuticals filed a 424B3 prospectus for the resale of up to 220,421,800 ordinary shares represented by 4,408,436 American Depositary Shares issuable upon exercise of Series P warrants from a September 2026 private placement. The company will not receive proceeds from the selling shareholder's sales, though it may receive proceeds from warrant exercises.

For details, click here →How to read a 424B3 →

Key details

Ordinary shares registered for resaleGBP 220.4M
American Depositary Shares registered for resale$4.4M
Last reported closing price per ADS on September 29, 2026$1
IssuerBiodexa Pharmaceuticals Plc

How BDRX stock reacted

Close before

$4.91

Oct 5, 2026

First close after

-3.11%

$4.76

5 trading days

-37.61%

$3.07

Since filing

-49.73%

$2.47

✦ Ask GOAX AI about this filing — what it means for BDRX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for BDRX?

Click here

Frequently asked questions

What did BDRX file with the SEC on Oct 6, 2026?

BDRX filed a 424B3 (Secondary offering). Biodexa Pharmaceuticals filed a 424B3 prospectus for the resale of up to 220,421,800 ordinary shares represented by 4,408,436 American Depositary Shares issuable upon exercise of Series P warrants from a September 2026 private placement. The company will not receive proceeds from the selling shareholder's sales, though it may receive proceeds from warrant exercises.

What does a secondary offering mean for BDRX stock?

New shares dilute existing holders and are often sold at a discount to the market price.

How do I read a 424B3?

The final terms of an offering of shares or bonds. Look at price, number of shares and the discount to the market price. Large offerings dilute existing shareholders.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 424B3 (prospectus (offering)): The final terms of an offering of shares or bonds.

How did BDRX stock react to this filing?

BDRX closed at $4.91 before the filing and $4.76 on Oct 6, 2026 (-3.11%). Five trading days later: $3.07 (-37.61%).

Other BDRX SEC filings

Get alerts when BDRX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
BDRX overviewBDRX analysisBDRX newsLatest SEC filings